CardioVascular and Interventional Radiology

, Volume 34, Issue 4, pp 774–785

Safety Profile of Sequential Transcatheter Chemoembolization with DC Bead: Results of 237 Hepatocellular Carcinoma (HCC) Patients

Authors

    • Imaging and Research Unit, Evgenidion University Hospital
    • 2nd Department of RadiologyAttikon University Hospital
  • Mary Pomoni
    • Imaging and Research Unit, Evgenidion University Hospital
  • Themistoklis N. Spyridopoulos
    • Imaging and Research Unit, Evgenidion University Hospital
    • 2nd Department of RadiologyAttikon University Hospital
  • Hippokratis Moschouris
    • Department of RadiologyTzanion Hospital
  • Alexis Kelekis
    • Imaging and Research Unit, Evgenidion University Hospital
    • 2nd Department of RadiologyAttikon University Hospital
  • Spyros Dourakis
    • Department of Internal MedicineUniversity of Athens
  • Efthymia Alexopoulou
    • 2nd Department of RadiologyAttikon University Hospital
  • John Koskinas
    • Department of Internal MedicineUniversity of Athens
  • Michalis Angelopoulos
    • Imaging and Research Unit, Evgenidion University Hospital
  • John Kornezos
    • Department of RadiologyTzanion Hospital
  • Anastasia Pomoni
  • Savvas Tandeles
    • Imaging and Research Unit, Evgenidion University Hospital
  • Athanasios Marinis
    • Department of SurgeryTzanion Hospital
  • Spyros Rizos
    • Department of SurgeryTzanion Hospital
  • Dimitrios Kelekis
    • Imaging and Research Unit, Evgenidion University Hospital
Clinical Investigation

DOI: 10.1007/s00270-010-0044-3

Cite this article as:
Malagari, K., Pomoni, M., Spyridopoulos, T.N. et al. Cardiovasc Intervent Radiol (2011) 34: 774. doi:10.1007/s00270-010-0044-3

Abstract

Introduction

Complications of chemoembolization performed with DC Bead loaded with doxorubicin (DEBDOX) of diameters 100–300 μm and 300–500 μm are presented in this paper. These diameters are currently the smallest available in drug-eluting technology.

Methods

Included are 237 patients who were treated with sequential DEBDOX with doxorubicin loaded at 37.5 mg/ml of DC Bead. The National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) were used to categorize complications.

Results

Thirty-day mortality was 1.26% (3/237). Incidence of grade 5 complications was 1.26% (3/237). Overall, grade 4 complications resulted in 5.48% (13/237) (irreversible liver failure, cholecystitis). Grade 2 liver function deterioration developed in 10 patients (4.2%). Cholecystitis/grade 2 and 4 incidents were observed in 3.6–5.06% across sessions (overall 13 patients; 5.48%). Postembolization Syndrome (PES) grade 1 or 2 was observed in up to 86.5%; however, grade 2 was observed in 25–42.19% across treatments. Pleural effusion was seen in eight patients (overall 3.37%; grade 1 in 1.8–3.7% across treatments; grade 3 in 0.42%). Grade 1 procedure-related laboratory pancreatitis was seen in 0.45%, and grade 2 gastrointestinal bleeding was seen in 0.84%. Procedure-associated skin erythema/grade 1 was seen in 0.84%. There was no correlation of liver failure or transient liver function deterioration with the diameter of the beads (p = 0.25–0.37 and p = 0.14–0.89, respectively). Stratifying with the diameter of the beads correlation values was: for cholecystitis (p = 0.11–0.96 across treatments), PES (p = 0.35–0.83), temporary/grade 1 elevation of liver enzymes (p = 0.002–0.0001), and bilirubin (p = 0.04–0.99).

Conclusions

DEBDOX chemoembolization is safe and small calibres do not result in increased complication rates compared with results of series using larger diameters of beads.

Keywords

Interventional oncologyEndovascular treatmentLiver/hepatic

Copyright information

© Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010